Clinical Research Directory
Browse clinical research sites, groups, and studies.
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
Sponsor: University of Saskatchewan
Summary
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and bevacizumab and to assess the association between an early FDG-PT/CT response and other clinical and pathological biomarkers and hepatic metastasectomy.
Official title: Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-05-01
Completion Date
2026-12-31
Last Updated
2025-05-09
Healthy Volunteers
No
Conditions
Interventions
FOLFOXIRI and Bevacizumab
Every 2 week for a total of 12 cycles
Locations (1)
Allan Balir Cancer Center
Regina, Saskatchewan, Canada